Compare OVLY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | CHRS |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.0M | 186.0M |
| IPO Year | N/A | 2014 |
| Metric | OVLY | CHRS |
|---|---|---|
| Price | $27.75 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.51 |
| AVG Volume (30 Days) | 8.4K | ★ 1.1M |
| Earning Date | 01-23-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.84 | 1.34 |
| Revenue | $79,783,000.00 | ★ $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.29 |
| P/E Ratio | $9.74 | ★ $0.96 |
| Revenue Growth | 2.98 | ★ 152.07 |
| 52 Week Low | $22.70 | $0.71 |
| 52 Week High | $32.24 | $1.89 |
| Indicator | OVLY | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 48.14 |
| Support Level | $27.66 | $1.18 |
| Resistance Level | $28.25 | $1.35 |
| Average True Range (ATR) | 0.45 | 0.09 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 68.28 | 67.80 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.